Category Archives: Safety

Lilly Increases Access to Clinical Trials Data

Eli Lilly and Company has announced it will begin sharing its clinical trial data with scientific researchers through www.clinicalstudydatarequest.com. The website, which houses data from several clinical trial sponsors, was created with support from PhRMA and EFPIA to increase access to and transparency of clinical trial results for researchers around the world.  
Also posted in E-Media, multimedia, R&D, Regulatory, Technology | Tagged , | Leave a comment

US Pharmacopeia Head Wants Fresh Outlook

In anticipation of the 200th anniversary of the United States Pharmacopeia (USP) in 2020, the organization’s new leadership is taking a fresh look at its role in setting standards for pharmaceutical development and production and how that has been altered by new regulatory policies and industry globalization. USP chief executive officer Ron Piervincenzi is consulting […]
Also posted in FDA, Regulatory | Tagged , , , | Leave a comment

Pfizer–AstraZeneca: Implications for the Future of International Pharma

By Peter O’ Donnell. The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry, but it is also revealing some remarkable displays of parochialism. Even the olympian Financial Times has been displaying some nationalistic sympathies that sit oddly with its customary laissez-faire liberalism. A recent editorial seemed to argue strongly for some form […]
Also posted in Deals, Europe, Global, Guest Blog, Op-Ed | Tagged , , | 2 Comments

The Fort Hood Killing and Psychotropic Drugs

In response to the recent shooting at Fort Hood that killed four (including the killer’s suicide) and wounded 16, the mental health watchdog Citizens Commission on Human Rights (CCHR) views this and other recent incidents as a wake-up call to the dangers of antidepressants, anti-psychotics and anti-anxiety drugs, which between them have accumulated 22 international drug […]
Posted in Safety | Tagged , , , | Leave a comment

Is Gender a Drug Safety Issue in the Era of Personalized Medicine?

By Lisa Henderson, Applied Clinical Trials. In January 2013, FDA told manufacturers to lower the dose of zolpidem, the insomnia treatment, for women, and suggested a 10 mg to 5 mg for immediate-release products (Ambien, Edluar, and Zolpimist) and from 12.5 mg to 6.25 mg for extended-release products (Ambien CR). That was based on evidence […]
Also posted in FDA, Gene therapy, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta